68
Participants
Start Date
May 31, 2012
Primary Completion Date
March 31, 2017
Study Completion Date
March 31, 2017
pazopanib in combination with weekly topotecan
"* Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~* Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
RECRUITING
Charité Campus Virchow-Klinikum, Berlin
Lead Sponsor
Collaborators (1)
GlaxoSmithKline
INDUSTRY
JSehouli
OTHER